Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Special Issues
Recent Advances in the Development, Characterization, and Stability Aspects of...
share announcement

Recent Advances in the Development, Characterization, and Stability Aspects of RNA-Based Vaccines

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: 20 February 2026 | Viewed by 1099

Special Issue Editors

Dr. Ravi Maharjan

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology, Dongguk University, Seoul 04620, Republic of Korea
Interests: mRNA vaccines; lyophilization; vaccine stability; continuous manufacturing
Special Issues, Collections and Topics in MDPI journals
Dr. Surin Hong

E-Mail Website
Guest Editor
Department of Biotechnology, College of Life Science, CHA University, Gyeonggi 13488, Republic of Korea
Interests: nanomaterial; drug delivery; nano biosensor; plasmonic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The rapid development and subsequent implementation of RNA-based vaccines during the global COVID-19 pandemic not only transformed the landscape of vaccine technology but also paved the way for novel therapeutic applications that were previously unimaginable. This particular Special Issue aims to compile and present the most recent and noteworthy advancements in the realm of RNA vaccine research, including but not limited to, lipid nanoparticle (LNP) formulation strategies, novel characterization methodology, cryoprotectants for lyophilization, and the impact of storage conditions on vaccine performance.

We extend a cordial invitation to researchers and scholars to submit their research or review article contributions to this Special Issue. Through state-of-the-art research and the promotion of collaborative efforts among scientists within this discipline, we hope to advance the collective understanding and practical applications of RNA technology. We strongly encourage authors to provide in-depth insights and comprehensive data that have the potential to inspire further research and development endeavors in this highly promising and rapidly evolving area of study.

Dr. Ravi Maharjan
Dr. Surin Hong
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • RNA-based vaccines
  • lyophilization
  • stability
  • gene therapy
  • formulation strategies
  • novel characterization
  • delivery systems
  • biopharmaceuticals
  • continuous manufacturing
  • AI/ML/digital twin

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 2633 KiB  
Review
Implications of Anaphylaxis Following mRNA-LNP Vaccines: It Is Urgent to Eliminate PEG and Find Alternatives
by Jinxing Song, Dihan Su, Hongbing Wu and Jeremy Guo
Pharmaceutics 2025, 17(6), 798; https://doi.org/10.3390/pharmaceutics17060798 - 19 Jun 2025
Viewed by 661
Abstract
The mRNA vaccine has protected humans from the Coronavirus disease 2019 (COVID-19) and has taken the lead in reversing the epidemic efficiently. However, the Centre of Disease Control (CDC) reported and raised the alarm of allergic or acute inflammatory adverse reactions after vaccination [...] Read more.
The mRNA vaccine has protected humans from the Coronavirus disease 2019 (COVID-19) and has taken the lead in reversing the epidemic efficiently. However, the Centre of Disease Control (CDC) reported and raised the alarm of allergic or acute inflammatory adverse reactions after vaccination with mRNA-LNP vaccines. Meanwhile, the US Food and Drug Administration (FDA) has added four black-box warnings in the instructions for mRNA-LNP vaccines. Numerous studies have proven that the observance of side effects after vaccination is indeed positively correlated to the level of anti-PEG antibodies (IgM or IgG), which are enhanced by PEGylated preparations like LNP vaccine and environmental exposure. After literature research and review in the past two decades, it was found that the many clinical trial failures (BIND-014, RB006 fell in phase II) of PEG modified delivery system or PEGylated drug were related to the high expression of anti-PEG IgM and IgG. In the background of shooting multiple mRNA-LNP vaccines in billions of people around the world in the past three years, the level of anti-PEG antibodies in the population may have significantly increased, which brings potential risks for PEG-modified drug development and clinical safety. This review summarizes the experience of using mRNA-LNP vaccines from the mechanism of the anti-PEG antibodies generation, detection methods, clinical failure cases of PEG-containing products, harm analysis of abuse of PEGylation, and alternatives. In light of the increasing prevalence of anti-PEG antibodies in the population and the need to avoid secondary injuries, this review article holds greater significance by offering insights for drug developers. It suggests avoiding the use of PEG excipients when designing PEGylated drugs or PEG-modified nano-formulations and provides references for strategies such as utilizing PEG-free or alternative excipients. Full article
(This article belongs to the Special Issue Recent Advances in the Development, Characterization, and Stability Aspects of RNA-Based Vaccines)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop